Published in J Virol on May 01, 1998
Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A (2001) 5.46
Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol (2002) 5.20
Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function. Proc Natl Acad Sci U S A (2002) 4.14
Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc Natl Acad Sci U S A (2004) 3.90
Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J Virol (1999) 3.13
Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol (2000) 2.85
The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci U S A (2000) 2.70
The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner. J Virol (2002) 2.66
Real-time visualization of HIV-1 GAG trafficking in infected macrophages. PLoS Pathog (2008) 2.32
Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of gag membrane targeting. J Virol (1999) 2.31
Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol (2000) 2.27
Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol (2004) 2.24
Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol (2001) 2.17
Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol (1999) 2.08
Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding. J Virol (2000) 2.07
Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc Natl Acad Sci U S A (2006) 1.87
Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression. J Virol (2003) 1.79
Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A (2005) 1.79
In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J Virol (2006) 1.70
Late domain-dependent inhibition of equine infectious anemia virus budding. J Virol (2004) 1.57
Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay. J Virol (2005) 1.55
Nucleocapsid protein function in early infection processes. Virus Res (2008) 1.53
Sequence-specific interaction between HIV-1 matrix protein and viral genomic RNA revealed by in vitro genetic selection. RNA (2001) 1.51
Somatic cell mutants resistant to retrovirus replication: intracellular blocks during the early stages of infection. Mol Biol Cell (1999) 1.47
Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation. J Virol (2006) 1.35
Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol (2000) 1.34
Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457). J Virol (2009) 1.33
Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting. J Mol Biol (2008) 1.31
Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity. J Virol (1999) 1.26
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res (2004) 1.26
Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat. Retrovirology (2010) 1.24
A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41. J Virol (2006) 1.22
Molecular determinants that regulate plasma membrane association of HIV-1 Gag. J Mol Biol (2011) 1.22
Interaction of Moloney murine leukemia virus matrix protein with IQGAP. EMBO J (2006) 1.19
RNA dimerization defect in a Rous sarcoma virus matrix mutant. J Virol (2000) 1.18
The conserved carboxy terminus of the capsid domain of human immunodeficiency virus type 1 gag protein is important for virion assembly and release. J Virol (2004) 1.18
A human nuclear shuttling protein that interacts with human immunodeficiency virus type 1 matrix is packaged into virions. J Virol (2000) 1.16
Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment. J Virol (2009) 1.15
Link between genome packaging and rate of budding for Rous sarcoma virus. J Virol (2003) 1.15
HIV type 1 Gag as a target for antiviral therapy. AIDS Res Hum Retroviruses (2011) 1.08
Second-site suppressors of HIV-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects. Retrovirology (2012) 1.06
Barrier-to-autointegration factor BAF binds p55 Gag and matrix and is a host component of human immunodeficiency virus type 1 virions. J Virol (2003) 1.06
Rescue of multiple viral functions by a second-site suppressor of a human immunodeficiency virus type 1 nucleocapsid mutation. J Virol (2000) 1.06
Mutations in human immunodeficiency virus type 1 nucleocapsid protein zinc fingers cause premature reverse transcription. J Virol (2008) 1.05
Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors. J Med Chem (2010) 1.04
Multiple functions for the basic amino acids of the human T-cell leukemia virus type 1 matrix protein in viral transmission. J Virol (1999) 1.03
Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription. J Virol (2007) 1.03
Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. J Virol (1998) 0.99
Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine. J Virol (2000) 0.97
African Swine Fever virus proteinase is essential for core maturation and infectivity. J Virol (2003) 0.95
Role of human immunodeficiency virus type 1 matrix phosphorylation in an early postentry step of virus replication. J Virol (2004) 0.94
Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription. J Virol (1999) 0.94
Viral protein U (Vpu)-mediated enhancement of human immunodeficiency virus type 1 particle release depends on the rate of cellular proliferation. J Virol (2001) 0.93
Global rescue of defects in HIV-1 envelope glycoprotein incorporation: implications for matrix structure. PLoS Pathog (2013) 0.92
PDZD8 is a novel Gag-interacting factor that promotes retroviral infection. J Virol (2010) 0.91
Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation. J Virol (2013) 0.91
A new retroelement constituted by a natural alternatively spliced RNA of murine replication-competent retroviruses. EMBO J (2003) 0.91
Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence. J Virol (2008) 0.90
Assembly and replication of HIV-1 in T cells with low levels of phosphatidylinositol-(4,5)-bisphosphate. J Virol (2011) 0.89
Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production. J Gen Virol (2008) 0.89
Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription. J Virol (2001) 0.89
A highly conserved residue in the C-terminal helix of HIV-1 matrix is required for envelope incorporation into virus particles. J Virol (2011) 0.89
Calmodulin disrupts the structure of the HIV-1 MA protein. J Mol Biol (2010) 0.85
Characterization of producer cell-dependent restriction of murine leukemia virus replication. J Virol (2002) 0.82
Incorporation of human immunodeficiency virus type 1 reverse transcriptase into virus-like particles. J Virol (2007) 0.82
Equine infectious anemia virus Gag p9 function in early steps of virus infection and provirus production. J Virol (2005) 0.82
The scaffolding protein Dlg1 is a negative regulator of cell-free virus infectivity but not of cell-to-cell HIV-1 transmission in T cells. PLoS One (2012) 0.81
Elucidating the mechanism by which compensatory mutations rescue an HIV-1 matrix mutant defective for gag membrane targeting and envelope glycoprotein incorporation. J Mol Biol (2015) 0.81
Efficient production of HIV-1 virus-like particles from a mammalian expression vector requires the N-terminal capsid domain. PLoS One (2011) 0.80
The RNA binding protein HuR does not interact directly with HIV-1 reverse transcriptase and does not affect reverse transcription in vitro. Retrovirology (2010) 0.79
HIV-1 Nef-associated Factor 1 Enhances Viral Production by Interacting with CRM1 to Promote Nuclear Export of Unspliced HIV-1 gag mRNA. J Biol Chem (2016) 0.78
Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396. J Virol (2016) 0.77
Deletions in the fifth alpha helix of HIV-1 matrix block virus release. Virology (2014) 0.76
Gene expression analysis of a panel of cell lines that differentially restrict HIV-1 CA mutants infection in a cyclophilin a-dependent manner. PLoS One (2014) 0.75
M2BP inhibits HIV-1 virion production in a vimentin filaments-dependent manner. Sci Rep (2016) 0.75
The matrix protein of human immunodeficiency virus is cleaved and packed into virion cores. Dokl Biol Sci (2006) 0.75
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (1988) 220.77
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol (1992) 12.89
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54
A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature (1993) 10.36
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A (1990) 8.23
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology (1987) 7.92
The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A (1994) 7.85
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A (1993) 6.44
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol (1997) 5.73
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Pathway of vesicular stomatitis virus entry leading to infection. J Mol Biol (1982) 5.21
Complete mutagenesis of the HIV-1 protease. Nature (1989) 5.16
A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci U S A (1994) 4.86
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc Natl Acad Sci U S A (1996) 4.83
Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol (1991) 4.74
Assembly and morphology of HIV: potential effect of structure on viral function. AIDS (1991) 4.73
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol (1992) 4.72
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45
HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell (1995) 4.41
Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production. J Virol (1994) 4.40
Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1994) 4.28
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell (1995) 4.25
Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol (1993) 4.20
Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol (1996) 4.15
Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. J Virol (1996) 4.08
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol (1995) 3.95
Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol (1992) 3.93
The human immunodeficiency virus type 1 encapsidation site is a multipartite RNA element composed of functional hairpin structures. J Virol (1996) 3.91
A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J Virol (1993) 3.75
Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J Virol (1993) 3.75
The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci U S A (1994) 3.65
Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol (1994) 3.47
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J Virol (1996) 3.19
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. J Virol (1993) 3.12
Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. J Virol (1997) 3.07
Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. J Virol (1994) 3.07
Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J Virol (1995) 3.04
A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A (1992) 3.01
Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures. Virology (1973) 2.94
Fatty acylation of proteins. Annu Rev Cell Biol (1988) 2.92
Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product. Virology (1992) 2.89
Direct interaction between the envelope and matrix proteins of HIV-1. EMBO J (1996) 2.75
Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells. J Virol (1996) 2.70
Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains. J Virol (1995) 2.59
Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J Virol (1989) 2.58
The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle. J Virol (1992) 2.51
Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35
The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J Virol (1996) 2.31
Mutations in gag proteins P12 and P15 of Moloney murine leukemia virus block early stages of infection. J Virol (1984) 2.30
Efficient particle formation can occur if the matrix domain of human immunodeficiency virus type 1 Gag is substituted by a myristylation signal. J Virol (1994) 2.21
Myristoylation of gag proteins of HIV-1 plays an important role in virus assembly. AIDS Res Hum Retroviruses (1990) 2.15
The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology (1995) 2.08
Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proc Natl Acad Sci U S A (1996) 2.01
Role of vif during packing of the core of HIV-1. Virology (1994) 2.01
HIV-1 infection of non-dividing cells. Nature (1994) 1.79
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J Virol (1996) 1.70
Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection. Cell (1997) 1.40
Characterization of human immunodeficiency virus type 1 matrix revertants: effects on virus assembly, Gag processing, and Env incorporation into virions. J Virol (1997) 1.40
Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis. J Virol (1997) 1.31
Amphipathic domains in the C terminus of the transmembrane protein (gp41) permeabilize HIV-1 virions: a molecular mechanism underlying natural endogenous reverse transcription. Proc Natl Acad Sci U S A (1996) 1.15
Influence of MA internal sequences, but not of the myristylated N-terminus sequence, on the budding site of HIV-1 Gag protein. Biochem Biophys Res Commun (1994) 1.13
Cytoskeleton-associated Pr65gag and retrovirus assembly. Virology (1983) 1.06
Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication. Virology (1997) 1.00
p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J Virol (1995) 6.87
Emergent impacts of multiple predators on prey. Trends Ecol Evol (1998) 5.82
Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A (2001) 5.46
Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol (1995) 4.27
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A (2003) 4.03
Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol (1995) 3.95
Massive outbreak of Escherichia coli O157:H7 infection in schoolchildren in Sakai City, Japan, associated with consumption of white radish sprouts. Am J Epidemiol (1999) 3.75
Measles virus P gene codes for two proteins. J Virol (1985) 3.31
Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus. J Virol (1999) 3.13
Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J Virol (2000) 2.85
The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions. Proc Natl Acad Sci U S A (2000) 2.70
Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J Virol (1995) 2.43
Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother (2001) 2.35
Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail. J Virol (2000) 2.27
Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J Virol (2001) 2.17
Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis (1996) 2.15
Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding. J Virol (2000) 2.07
The role of envelope glycoprotein processing in murine leukemia virus infection. J Virol (1987) 2.06
NMR scalar couplings across Watson-Crick base pair hydrogen bonds in DNA observed by transverse relaxation-optimized spectroscopy. Proc Natl Acad Sci U S A (1998) 1.99
An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences. J Virol (1994) 1.81
HIV-1 infection of non-dividing cells. Nature (1994) 1.79
The nucleotide sequence of the mRNA encoding the fusion protein of measles virus (Edmonston strain): a comparison of fusion proteins from several different paramyxoviruses. Virology (1986) 1.76
Matrix genes of measles virus and canine distemper virus: cloning, nucleotide sequences, and deduced amino acid sequences. J Virol (1986) 1.74
Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res Hum Retroviruses (1996) 1.74
Decreased tensile strength of an epidural catheter during its removal by grasping with a hemostat. Anesth Analg (2001) 1.72
Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. Proc Natl Acad Sci U S A (1999) 1.61
Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. Ann Intern Med (1992) 1.53
Synthesis of deoxyoligonucleotides containing 7-deazaadenine: recognition and cleavage by restriction endonuclease Bgl II and Sau 3AI (nucleosides and nucleotides Part 55). Nucleic Acids Res (1984) 1.50
Cellular motor protein KIF-4 associates with retroviral Gag. J Virol (1999) 1.43
Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy (2012) 1.41
Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection. Cell (1997) 1.40
Characterization of human immunodeficiency virus type 1 matrix revertants: effects on virus assembly, Gag processing, and Env incorporation into virions. J Virol (1997) 1.40
Synthesis of decadeoxyribonucleotides containing N6-methyladenine, N4-methylcytosine, and 5-methylcytosine: recognition and cleavage by restriction endonucleases (nucleosides and nucleotides part 74). Nucleic Acids Res (1987) 1.27
Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity. J Virol (1999) 1.26
On the mechanism of DNA-adenine methylase. J Biol Chem (1988) 1.20
Molecular dynamics of MHC genesis unraveled by sequence analysis of the 1,796,938-bp HLA class I region. Proc Natl Acad Sci U S A (1999) 1.19
Cry j I, a major allergen of Japanese cedar pollen, has pectate lyase enzyme activity. Allergy (1995) 1.19
Nucleotide sequencing analysis of the 146-kilobase segment around the IkBL and MICA genes at the centromeric end of the HLA class I region. Genomics (1998) 1.15
Nucleotide sequence analysis of the HLA class I region spanning the 237-kb segment around the HLA-B and -C genes. Genomics (1997) 1.13
Mutational analysis of the fusion peptide of the human immunodeficiency virus type 1: identification of critical glycine residues. Virology (1996) 1.12
Positive identification of a measles virus cDNA clone encoding a region of the phosphoprotein. J Virol (1984) 1.11
Analysis of HIV-1 envelope mutants and pseudotyping of replication-defective HIV-1 vectors by genetic complementation. AIDS Res Hum Retroviruses (1992) 1.10
HLA antigens and myasthenia gravis in Japan. J Neurol Sci (1977) 1.08
Potential remedy against Echinococcus multilocularis in wild red foxes using baits with anthelmintic distributed around fox breeding dens in Hokkaido, Japan. Parasitology (2002) 1.07
DNA duplex dynamics: NMR relaxation studies of a decamer with uniformly 13C-labeled purine nucleotides. J Magn Reson (1998) 1.06
Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis. J Virol (2001) 1.04
The synthesis and properties of oligodeoxyribonucleotides containing N6-methoxyadenine. Nucleic Acids Res (1992) 1.03
The effect of cryotherapy on intraarticular temperature and postoperative care after anterior cruciate ligament reconstruction. Am J Sports Med (1999) 1.02
Transformation of NIH 3T3 cells by cotransfection with c-src and nuclear oncogenes. Mol Cell Biol (1987) 1.02
Minor-groove-modified oligonucleotides: synthesis of decadeoxynucleotides containing hypoxanthine, N2-methylguanine and 3-deazaadenine, and their interactions with restriction endonucleases Bgl II, Sau, 3AI, and Mbo I (Nucleosides and Nucleotides Part 75). Nucleic Acids Res (1987) 1.02
The effect of cortical bone thickness on the stability of orthodontic mini-implants and on the stress distribution in surrounding bone. Int J Oral Maxillofac Surg (2008) 1.02
Evaluation of the structural proteins of the hamster neurotropic strain of measles virus with monoclonal antibodies. J Neuroimmunol (1986) 1.01
Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. Int J Gynecol Cancer (2006) 1.00
Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. J Virol (1998) 0.99
Base analog N6-hydroxylaminopurine mutagenesis in Escherichia coli: genetic control and molecular specificity. Mutat Res (1996) 0.99
Selective cellular natural killing against human leukaemic T cells and thymus. Nature (1977) 0.98
Short-term self-treatment of travellers' diarrhoea with norfloxacin: a placebo-controlled study. J Antimicrob Chemother (1989) 0.97
Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine. J Virol (2000) 0.97
Effect of resistive knee extension training on postural control measures in middle aged and elderly persons. J Physiol Anthropol Appl Human Sci (2000) 0.96
Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function. AIDS Res Hum Retroviruses (1992) 0.95
Chymotryptic subfragments of troponin T from rabbit skeletal muscle. Interaction with tropomyosin, troponin I and troponin C. J Biochem (1983) 0.95
Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol (1999) 0.94
Gastric non-Hodgkin's lymphoma associated with Behçet's disease. Intern Med (1993) 0.94
NMR with 13C, 15N-doubly-labeled DNA: the Antennapedia homeodomain complex with a 14-mer DNA duplex. J Biomol NMR (1998) 0.94
Hepatocyte nuclear factor-4 alpha gene mutations in Japanese non-insulin dependent diabetes mellitus (NIDDM) patients. Res Commun Mol Pathol Pharmacol (1996) 0.93
Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis (1990) 0.92
Potent and stable attenuation of live-HIV-1 by gain of a proteolysis-resistant inhibitor of NF-kappaB (IkappaB-alphaS32/36A) and the implications for vaccine development. J Biol Chem (1999) 0.92
Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea. J Antimicrob Chemother (1987) 0.92
Accelerated decline of blood glucose after intravenous glucose injection in a patient with Cowden disease having a heterozygous germline mutation of the PTEN/MMAC1 gene. Anticancer Res (2000) 0.91
Late male-killing phenomenon found in a Japanese population of the oriental tea tortrix, Homona magnanima (Lepidoptera: Tortricidae). Heredity (Edinb) (2001) 0.91
Animal model of systemic carnitine deficiency: analysis in C3H-H-2 degrees strain of mouse associated with juvenile visceral steatosis. Biochem Biophys Res Commun (1991) 0.91
Solution structure of an RNA duplex including a C-U base pair. Biochemistry (2000) 0.91
Meticillin-resistant Staphylococcus aureus and meticillin-susceptible S. aureus pneumonia: comparison of clinical and thin-section CT findings. Br J Radiol (2011) 0.90
Radiological findings in acute Haemophilus influenzae pulmonary infection. Br J Radiol (2011) 0.89
Acute Klebsiella pneumoniae pneumonia alone and with concurrent infection: comparison of clinical and thin-section CT findings. Br J Radiol (2010) 0.89
Mutagenicity of 5-bromouracil and N6-hydroxyadenine studied by yeast oligonucleotide transformation assay. Mutat Res (1994) 0.89
Effects of second-site mutations on dominant interference by a human immunodeficiency virus type 1 envelope glycoprotein mutant. J Virol (1995) 0.89
Periodic leg movements during either epidural or spinal anesthesia in an elderly man without sleep-related (nocturnal) myoclonus. Sleep (1990) 0.89
Thoracic extramedullary hematopoiesis associated with hereditary spherocytosis. Intern Med (1992) 0.88
Tumor necrosis factor-alpha induces vascular hyporesponsiveness in Sprague-Dawley rats. Life Sci (1992) 0.88
Inhibition of complement components C3 and C4 by cadralazine and its active metabolite. Eur J Clin Pharmacol (1991) 0.87
Synthesis of decadeoxyribonucleotides containing 5-modified uracils and their interactions with restriction endonucleases Bgl II, Sau 3AI and Mbo I (nucleosides and nucleotides 82). Nucleic Acids Res (1988) 0.87
Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus. Hum Gene Ther (1992) 0.87
Species-specific differences in coumarin-induced hepatotoxicity as an example toxicogenomics-based approach to assessing risk of toxicity to humans. Hum Exp Toxicol (2008) 0.87
Primary malignant hemangiopericytoma of the breast: report of a case. Surg Today (1999) 0.86
H...N hydrogen bond lengths in double stranded DNA from internucleotide dipolar couplings. J Biomol NMR (2001) 0.86
Acute renal infarction in a patient with left atrial myxoma. Clin Nephrol (2007) 0.85
Isolation of cDNA and genomic clones of a human Ras-related GTP-binding protein gene and its chromosomal localization to the long arm of chromosome 7, 7q36. Genomics (1996) 0.85
A novel traction system for esophageal endoscopic submucosal dissection. Endoscopy (2012) 0.85
Trimethadione tolerance test for evaluation of functional reserve of the liver in patients with liver cirrhosis and esophageal varices. J Pharmacobiodyn (1986) 0.85
Thin-section CT findings of patients with acute Streptococcus pneumoniae pneumonia with and without concurrent infection. Br J Radiol (2012) 0.85
Crystallographic studies on damaged DNAs. II. N(6)-methoxyadenine can present two alternate faces for Watson-Crick base-pairing, leading to pyrimidine transition mutagenesis. J Mol Biol (1999) 0.84